OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 18
- Registration Number
- NCT05015673
- Locations
- πΊπΈ
SDS Clinical Trials, Inc., Orange, California, United States
πΊπΈSleepMed of South Carolina, Columbia, South Carolina, United States
πΊπΈTodd Swick, MD PA, Houston, Texas, United States
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 21
- Registration Number
- NCT04865835
- Locations
- πΊπΈ
Hassman Research Institute, Marlton, New Jersey, United States
πΊπΈAt Fort Lauderdale Behavioral Health Center, Oakland Park, Florida, United States
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-02-02
- Target Recruit Count
- 122
- Registration Number
- NCT04830215
- Locations
- π¨π¦
Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-07-13
- Target Recruit Count
- 50
- Registration Number
- NCT04786730
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, San Antonio, Texas, United States
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Conditions
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-09-15
- Target Recruit Count
- 20
- Registration Number
- NCT04786574
- Locations
- πΊπΈ
Johns Hopkins Pediatric Specialty Clinic, Baltimore, Maryland, United States
πΊπΈNorthwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatology, Chicago, Illinois, United States
π¬π§Great Ormond Street, London, United Kingdom
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-10-21
- Target Recruit Count
- 10
- Registration Number
- NCT04782258
- Locations
- πΊπΈ
Riley Hospital for Children, Indianapolis, Indiana, United States
πΊπΈJohns Hopkins Pediatric Specia, Baltimore, Maryland, United States
πΊπΈC.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 386
- Registration Number
- NCT04770285
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, Dallas, Texas, United States
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-10-10
- Target Recruit Count
- 241
- Registration Number
- NCT04464564
- Locations
- πΊπΈ
Clinical Research Site #840-020, Phoenix, Arizona, United States
πΊπΈClinical Research Site #840-006, Panorama City, California, United States
πΊπΈClinical Research Site #840-039, Hallandale, Florida, United States
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-10-10
- Target Recruit Count
- 183
- Registration Number
- NCT04408755
- Locations
- πΊπΈ
Clinical Research Site #840-012, Kissimmee, Florida, United States
πΊπΈClinical Research Site #840-069, Maitland, Florida, United States
πΊπΈClinical Research Site #840-083, Maitland, Florida, United States
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2022-06-02
- Target Recruit Count
- 32
- Registration Number
- NCT04398225
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, Hollywood, Florida, United States